

Contents

Abstract.....	i
Résumé	iii
List of abbreviations.....	v
1 Introduction	1
1.1 Sulfasalazine in a historical and medical perspective.....	3
1.2 Tetrahydrobiopterin biosynthesis and regulation.....	6
1.3 The inhibitory effect of sulfasalazine on sepiapterin reductase.....	9
1.3.1 Consequences of SPR inhibition by sulfasalazine	10
1.4 Tetrahydrobiopterin dependent enzymes.....	11
1.4.1 Tetrahydrobiopterin and relevance in specific diseases	13
1.5 The enzymatic mechanism of sepiapterin reductase	15
2 Aim of the project.....	19
3 Results and discussion	21
3.1 Validation of sepiapterin reductase inhibition	21
3.1.1 Validation of sepiapterin reductase inhibition in vitro by a enzymatic activity assay...	21
3.1.2 Validation of sepiapterin reductase inhibition in cellulo by measuring intracellular total biopterin levels in cells supplemented with sepiapterin	23
3.2 Screening for other inhibitors of sepiapterin reductase	26
3.2.1 A high-throughput screen based on time-resolved FRET	27
3.2.2 Potent sepiapterin reductase inhibitors	31
3.3 Validation of the screen hits.....	32
3.3.1 Validation by an enzymatic based activity assay	32
3.3.2 Validation in a cell based assay.....	33
3.4 Intracellular inhibition of sepiapterin reductase	34
3.4.1 Biologically relevant tetrahydrobiopterin measurements	34

3.4.2	Catecholamine measurements	39
3.4.3	In vivo relevant effects of sepiapterin reductase inhibition.....	42
3.5	Mechanistic study of sepiapterin reductase.....	43
3.5.1	Detailed kinetic description of sepiapterin reductase.....	43
3.5.2	Cofactor preference of sepiapterin reductase inhibitors based on time-resolved FRET	45
3.6	A binding study of sepiapterin reductase by isothermal calorimetric titration	45
3.6.1	Binding of cofactor to sepiapterin reductase	46
3.6.2	Cofactor dependence for sulfa drug binding	48
3.6.3	Formation of a ternary binding complex between sepiapterin reductase, cofactor and sulfa drugs.....	49
3.7	Inhibition of sepiapterin reductase through the formation of a ternary complex with sulfasalazine and NADP ⁺	52
3.7.1	Formation of a ternary complex of sulfasalazine and NADP ⁺ with human sepiapterin reductase	52
3.7.2	Binding of different sulfonamides	56
4	Concluding remarks and future perspectives	61
5	Methods.....	65
5.1	General information	65
5.2	Validation of sepiapterin reductase inhibition in vitro by a enzymatic activity assay.....	65
5.3	SDS-PAGE	66
5.4	Drug toxicity assay based on cell viability.....	66
5.5	Validation of sepiapterin reductase inhibition in cellulo by measuring intracellular total biopterin levels in cells supplemented with sepiapterin.....	67
5.6	Bradford assay	68
5.7	Coupling of sulfasalazine to synthetic fluorophores Alexa488 and Alexa549.....	68
5.8	Screening for other sepiapterin reductase inhibitors by a SNAP-based competition time- resolved FRET assay	69

5.9	Screen validation by enzymatic based activity assay	71
5.10	Screen validation in a cell based assay	71
5.11	Measurement of endogenous intracellular biopterin and BH ₄ levels in PC12 cells	72
5.12	Pterin measurements in human fibroblasts	73
5.13	Catecholamine measurements	74
5.13.1	Detection of dopamine in rat PC12	74
5.13.2	L-DOPA and 3-MT measurements in SK-N-BE(2)	75
5.14	Detailed kinetic description	75
5.14.1	Determination of K _m and V _{max} by an enzymatic activity assay	75
5.14.2	Cofactor preference of sepiapterin reductase inhibitors	76
5.14.3	Mutation of human sepiapterin reductase	77
5.15	A binding study by isothermal calorimetric titration	77
5.15.1	Expression and purification	77
5.15.2	Binding of NADPH/NADP ⁺ to sepiapterin reductase	78
5.15.3	Cofactor dependence for sulfa drug binding	79
5.15.4	Formation of a ternary binding complex between sepiapterin reductase, cofactor and sulfa drugs	80
5.16	Crystals of sepiapterin reductase and sulfonamides	80
5.16.1	Expression, purification and crystallisation	80
5.16.2	Screening for optimal crystal conditions	81
5.16.3	Final crystallisation conditions	81
5.16.4	Data processing and model refinement	81
6	Appendix	83
6.1	Crystal data	83
6.2	Amino acid sequences	86
6.3	Primer list	90
6.4	ITC data	91

6.4.1	Binding of cofactor to sepiapterin reductase	91
6.4.2	Cofactor dependence for sulfa drug binding	93
6.4.3	Formation of a ternary binding complex between sepiapterin reductase, cofactor and sulfa drugs.....	94
7	References	97
8	Curriculum Vitae	103
9	Acknowledgements	107